Premium
Combined evaluation of resting IGF‐I, N‐terminal propeptide of type III procollagen (PIIINP) and C‐terminal cross‐linked telopeptide of type I collagen (ICTP) levels might be useful for detecting inappropriate GH administration in athletes: a preliminary report
Author(s) -
Sartorio Alessandro,
Agosti Fiorenza,
Marazzi Nicoletta,
Maffiuletti Nicola A.,
Cella Silvano G.,
Rigamonti Antonello E.,
Guidetti Laura,
Di Luigi Luigi,
Muller Eugenio E.
Publication year - 2004
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2004.02129.x
Subject(s) - n terminal telopeptide , procollagen peptidase , medicine , endocrinology , type i collagen , biology , alkaline phosphatase , biochemistry , osteocalcin , enzyme
Summary objective To verify whether combined measurements of GH‐dependent parameters might be useful in detecting exogenous recombinant GH (rGH) administration in male athletes from different disciplines. methods Sixty‐six athletes (control group) were sampled for the evaluation of resting IGF‐I, N‐terminal propeptide of type III procollagen (PIIINP) and telopeptide type I collagen (ICTP). Cut‐off values (mean + 2 SD) for IGF‐I, PIIINP and ICTP were calculated and arbitrary scores (1·5, 2·0) were assigned to abnormal parameters. By using the sum of individual parameter scores, positive (≥ 3) or negative (< 3) scores were obtained. In addition, a subgroup of six athletes was treated for 3 weeks with rGH (0·09 IU/kg body weight, 6 days/week) and was similarly evaluated at the end of the 1st, 2nd and 3rd week (i.e. 18 samples). results Abnormal IGF‐I, or PIIINP or ICTP levels were found, respectively, in one, two and four subjects (1·5–6·1%) of the control group (in the younger athletes); only one 19‐year‐old subject of this group obtained a positive score. Abnormal IGF‐I, PIIINP and ICTP levels were found in 61·1–66·7% samples of the treated group. Positive cases were 3/6 at the 1st and 2nd week and 6/6 at the 3rd week. The sensitivity of the screening approach was 50–100% (at the 1st−2nd and 3rd week, respectively) and specificity was 98·5%. conclusion This ‘first level’ screening test is safe, acceptable and relatively inexpensive. Further additional investigations of ‘second level’ (i.e. GH secretory profile, GH response to a GH‐releasing peptide) can be retained to validate or exclude rGH administration or for the early diagnosis of infrequent endogenous GH hypersecretion.